New weight-loss drug combines naltrexone and bupropion
However, the withdrawal rates from earlier trials was as high as 50%
A new combination weight loss pill has been approved by the TGA for use nearly 15 years after it was developed by an Australian physiologist.
The medication (Contrave, by iNova) contains a combination of the opioid antagonist naltrexone and the anti-cravings drug bupropion.
